Lee Myung-Ah, Byun Jae-Ho, Shim Byoung-Young, Woo In-Sook, Kang Jin-Hyung, Hong Young Seon, Lee Kyung Shik, Choi Myung Gyu, Chang Suk Kyun, Oh Seong Taek, Choi Sung Il, Lee Doo Suk
Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.
Korean J Intern Med. 2005 Sep;20(3):205-9. doi: 10.3904/kjim.2005.20.3.205.
Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer. Therefore, we evaluated the efficacy and safety of irinotecan, 5-FU and a low dose of LV (modified FOLFIRI) as a first line of therapy for patients with relapsed or metastatic colorectal cancer.
Between January 2002 and October 2004, 44 patients with histologically confirmed recurrent or metastatic colorectal cancer were enrolled. The chemotherapy regimen schedule consisted of 180 mg/m2 of irinotecan being administered intravenously (i.v) on Day 1, 400 mg/m2 of 5-FU via i.v bolus with 600 mg/m2 of continuous infusion for 22 hrs on both Day 1 and 2, and 20 mg/m2 of leucovorin on both Day 1 and 2 , repeated every two weeks.
The overall response rate was 47.8%. Of the 40 evaluated patients, one had CR (2.3%) and 20 had PR (46.5%). Toxicities were mild and easily manageable. Three patients experienced 23 episodes of Grade 3/4 leukopenia., Only one patient developed Grade 3/4 diarrhea. None experienced Grade 3/4 thrombocytopenia.
Modified FOLFIRI with a low dose of LV is an effective and tolerable regimen for patients with recurrent or metastatic colorectal cancer.
伊立替康联合5-氟尿嘧啶（5-FU）和高剂量亚叶酸（LV），即FOLFIRI方案，已显示出对复发或转移性结直肠癌有活性。因此，我们评估了伊立替康、5-FU和低剂量LV（改良FOLFIRI）作为复发或转移性结直肠癌患者一线治疗的疗效和安全性。
在2002年1月至2004年10月期间，纳入了44例经组织学确诊为复发或转移性结直肠癌的患者。化疗方案为第1天静脉注射（i.v）180mg/m²伊立替康，第1天和第2天静脉推注400mg/m² 5-FU并持续输注600mg/m² 22小时，第1天和第2天静脉注射20mg/m²亚叶酸，每两周重复一次。
总缓解率为47.8%。在40例可评估患者中，1例完全缓解（CR，2.3%），20例部分缓解（PR，46.5%）。毒性反应轻微且易于控制。3例患者发生23次3/4级白细胞减少。仅1例患者发生3/4级腹泻。无患者发生3/4级血小板减少。
低剂量LV的改良FOLFIRI方案对复发或转移性结直肠癌患者是一种有效且可耐受的方案。
